Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Compassion and Association: Building Significant Connections - 2Exploring Asia’s Realm of Flying Snakes
- 3Instructions to Pick the Ideal SUV Size for Seniors
- 4Well known SUVs With Low Energy Utilization In 2024
- 5The newest 'Project Hail Mary' trailer shows Ryan Gosling befriending an alien in Phil Lord and Chris Miller's space epic
- Israeli naval intelligence reduces Iranian threat to Strait of Hormuz
- Israel, Gulf states report fresh missile and drone attacks
- 'Israel has the right to continue its attacks,' Lebanese Foreign Minister announces
- New materials, old physics – the science behind how your winter jacket keeps you warm
- I visited every country by 25. Antarctica showed me how much I still hadn't seen.
- With more Moon missions on the horizon, avoiding crowding and collisions will be a growing challenge
- The Job of a Migration Legal advisor: How They Can Help You
- Novo Nordisk cuts Wegovy price as CEO pledges to go 'all in' on weight loss pill
- Australia’s post-Bondi crackdown accused of targeting pro-Palestinian voices
